Insulin-like growth factor II mRNA-binding protein 3 expression correlates with poor prognosis in acral lentiginous melanoma
Journal
PLoS ONE
Journal Volume
11
Journal Issue
1
Pages
e0147431
Date Issued
2016
Author(s)
Lin M.-H.
Jee S.-H.
Chue C.-Y.
Abstract
Insulin-like growth factor-II mRNA-binding protein 3 (IMP-3) is an RNA-binding protein expressed in multiple cancers, including melanomas. However, the expression of IMP-3 has not been investigated in acral lentiginous melanoma (ALM). This study sought to elucidate its prognostic value in ALMs. IMP-3 expression was studied in 93 patients diagnosed with ALM via immunohistochemistry. Univariate and multivariate analyses for survival were performed, according to clinical and histologic parameters, using the Cox proportional hazard model. Survival curves were graphed using the Kaplan-Meier method. IMP-3 was over-expressed in 70 out of 93 tumors (75.3%). IMP-3 expression correlated with thick and high-stage tumor and predicted poorer overall, melanoma-specific, recurrence-free and distant metastasis-free survivals (P = 0.002,0.006,0.008 and 0.012, respectively). Further analysis showed that patients with tumor thickness ? 4.0 mm and positive IMP-3 expression had a significantly worse melanoma-specific survival than those without IMP-3 expression (P = 0.048). IMP-3 (hazard ratio 3.67, 95% confidence intervals 1.35-9.97, P = 0.011) was confirmed to be an independent prognostic factor for melanoma-specific survival in multivariate survival analysis. Positive IMP-3 expression was an important prognostic factor for ALMs. ? Sheen 2016 et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
SDGs
Other Subjects
B Raf kinase; insulin like growth factor II binding protein 3; somatomedin binding protein; unclassified drug; IMP3 protein, human; RNA binding protein; tumor marker; acral lentiginous melanoma; adult; aged; Article; BRAF gene; cancer localization; cancer prognosis; cancer specific survival; cancer staging; cancer survival; cohort analysis; controlled study; cutaneous melanoma; distant metastasis free survival; female; gene mutation; histopathology; human; human tissue; immunohistochemistry; KIT gene; lymph node metastasis; major clinical study; male; metastatic melanoma; mutational analysis; oncogene N ras; oncological parameters; overall survival; protein expression; recurrence free survival; retrospective study; survival prediction; tumor thickness; ulcer; enzyme immunoassay; foot disease; melanoma; metabolism; middle aged; mortality; pathology; prognosis; risk factor; secondary; skin tumor; survival rate; tumor recurrence; very elderly; young adult; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Female; Foot Diseases; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Risk Factors; RNA-Binding Proteins; Skin Neoplasms; Survival Rate; Young Adult
Publisher
Public Library of Science
Type
journal article